WO1995022319A1 - Process for preparing fine particle pharmaceutical formulations - Google Patents
Process for preparing fine particle pharmaceutical formulations Download PDFInfo
- Publication number
- WO1995022319A1 WO1995022319A1 PCT/US1995/001943 US9501943W WO9522319A1 WO 1995022319 A1 WO1995022319 A1 WO 1995022319A1 US 9501943 W US9501943 W US 9501943W WO 9522319 A1 WO9522319 A1 WO 9522319A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- extrusion aid
- fine particle
- extrusion
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Definitions
- This invention relates pharmaceutical formulation processes. More particularly, the present invention concerns a process for preparing fine particle pharmaceutical formulations by extrusion/spheronization.
- the size of particles produced by the above method is limited to particle sizes ranging above about 0.5 mm.
- the amount of water added in the wetting step must be carefully controlled. Excess water causes the extrudate in the extrusion step to take on the consistency of "mud" while too little water causes the wetted material to rupture the screens of the extrusion equipment. The result is that without very careful process control of the amount of water added to the formulation in the wetting step, batches may be unacceptable with attendant loss of time and/or money.
- This invention provides a process having improved throughput for preparing fine particle pharmaceutical formulations which exhibit improved uniformity of particle size and performance characteristics such as drug release.
- the process is useful for the preparation of formulations comprising fine particles having particle sizes ranging between about 0.05 mm and about 1 mm which may be used as a sprinkle formulation for administering a therapeutically active compound to a patient.
- the particles may also be used in suspensions, and as a component of tablets and capsules.
- oils and waxes having a drop point ranging between about 15°C and 115°C; b) thoroughly blending the dry mixture; c) wetting the mixture resulting from step b) to form a granular mixture of the formulation; d) extruding the granular mixture through a mesh; e) spheronizing the extrudate; and f) drying the fine particles resulting from step e) to form a fine particle formulation.
- the present invention provides a method for making fine particulate formulations that can be used to administer therapeutically active compounds to a patient.
- the process has three distinct advantages over prior art processes for making fine particle formulations: first, the amount of wetting agent (e.g. water or water containing one or more additives) added to the blend of dry ingredients in the wetting step does not need to be as carefully controlled; second, the process is capable of producing fine particle formulations in which the particle size may be less than 0.5 mm; and third, the particle size and the performance characteristics of the fine particle formulations produced is more uniform than that resulting from prior art processes.
- wetting agent e.g. water or water containing one or more additives
- the formed particles may contain one or more therapeutically active compounds, including pharmaceutically acceptable salts, esters, amides and prodrugs.
- the therapeutically active compounds may be any therapeutically active compounds for which oral administration is desired.
- the selected therapeutically active compound should be compatible with the selected extrusion aid material and any excipients.
- therapeutically active compounds include, but are not limited to: ⁇ -adrenergic agonists such as clonidine and pseudoephedrine; analgesics such as acetaminophen, aspirin, and ibuprofen; antianginals such as verapamil and nifedipine; antibacterials (antibiotics) such as penicillin, erythromycin, tetracycline, amoxicillin, trimethoprim and clarithromycin; antidepressants such as imipramine; antiinflammatory agents such as indomethacin and zileuton; antimigrane agents such as ergotamine; antineoplastics such as methotrexate and etoposide; antivirals such as acyclovir and zidovudine; calcium channel blockers such as diltiazem and verapamil; cardiotonic agents such as digoxin; expectorants such as quaifenesin; bronchodial
- pharmaceutically acceptable salts, esters, amides and prodrugs refers to those carboxylate salts, amino acid addition salts, esters, amides and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, as well as the zwitterionic forms, where possible, of the compounds of the invention.
- salts refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.
- Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laureate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactiobionate, and laurylsulphonate salts and the like.
- alkali and alkaline earth metals such as sodium, lithium, potassium, calcium, magnesium, and the like
- non-toxic ammonium, quaternary ammonium and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine and the like (cf. S. M. Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci.. 66: 1-19 (1977).
- esters of the compounds of this invention include Ci to C4 alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C5 to C7 cycloalkyl esters as well as arylalkyl esters such as, but not limited to, benzyl, phenyethyl, phenylpropyl and the like. Ci to C4 alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.
- Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary Ci to C6 alkyl amines and secondary Ci to C dialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines the amine may also be in the form of a 5 or 6 membered heterocycle containing one nitrogen atom. Amides derived from ammonia, to C3 alkyl primary amides and Ci to C2 dialkyl secondary amides /22319
- Amides of the compounds of the invention may be prepared according to conventional methods.
- pro-drug referes to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood.
- a thorough discussion is provided in T. Higuchi and V. Stella, "Pro-drugs as Novel Delivery Systems", Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987
- the therapeutically active agent is present in the formulation in an amount up to about 90 percent by weight of the entire composition.
- the extrusion aid is selected so that it does not detrimentally interact with the therapeutically active compound or any excipients and so that it is biocompatible.
- the extrusion aid is a material having a drop point in the range of 15°C to about 115 ⁇ C.
- drop point as used throughout this specification and claims is meant the temperature at which the material melts or softens to the point where it forms a drop and falls from the thermometer bulb used to take the drop point measurement.
- extrusion aid material or mixture of extrusion aid materials are also selected with regard to the properties of the therapeutically active compound. For example, if the therapeutically active compound degrades at a certain temperature, the extrusion aid material having a melting or softening temperature below the compound's degradation temperature is preferred.
- suitable extrusion aid materials include, but are not limited to: fats, fatty acid esters, hydrogenated vegetable oils, saturated polyglycolized glycerides of hydrogenated vegetable oils, polyethylene glycol esters of hydrogenated vegetable oils such as Lubritab®, Gelucires® and high molecular weight polyethylene glycols.
- extrusion aid materials include, but are not limited to, waxes such as carnauba wax, glyceryl esters of aliphatic acids, especially stearic, palmitic and oleic acids, cocoa butter, phospholipids such as lecithins, and sterols such as cholesterol.
- extrusion aid materials are Lubritab®, a hydrogenated vegetable oil NF obtainable form the Mendell Co. Carmel, NY, Compritol® 888 ATO, glyceryl behenate NF obtainable from Gattefosse, Westwood, NJ, and wax, preferably rnicronized wax.
- the extrusion aid material is present in the formulations made by the process of this invention in amounts ranging between about 1 percent by weight to about 75 percent by weight based upon the total weight of the formulation.
- Fine particle formulations prepared by the process of the present invention may take the form of so-called "sprinkle" formulations which are packaged in a paper, plastic, or foil cachet or in pull-apart capsules. The patient utilizes the formulation by tearing open the cachet or by pulling apart the capsule and then sprinkles the drug formulation over a food for ingestion.
- the fine particles produced by the method of the present invention may be sealed inside a capsule.
- the fine particles produced by the process of this invention may be dispersed within a convention tablet formulation.
- the formulations made by the process of this invention may thus contain ingredients in addition to the active therapeutic agent and the extrusion aid material which are chosen to tailor-make the final formulation for its intended purpose.
- disintegrating agents such as starch, cross-linked polyvinylpyrrolidone (Crospovidone), cross-linked cellulose (Croscarmelose), and sodium starch glycolate may be added to enhance the fast disintegration and dissolution of the fine particles.
- Suitable binder agents include polyvinylpyrrolidone (such as Povidone 30 and Povidone 90), carboxymethyl celluloses, and hydroxymethyl celluloses.
- fillers such as microcrystalline cellulose and lactose may be added to formulations made by the process of this invention.
- Microcrystalline cellulose extrudes well and undergoes spheronization well to aid in forming fine particles by the process of this invention and is a preferred filler.
- the formulation may also include various excipients which are generally chosen from excipients that are conventionally used in solid compositions, such as tablets.
- Preferred excipients include lactose, mannitol, microcrystalline cellulose (Avicel®) and vitamin E.
- the excipients, including fillers may be present in the composition in an amount of about 75 percent to 90 percent by weight based upon the weight of the formulation.
- the particles can also be coated, for example, with an enteric coating or a coating which masks any unpleasant taste of the ingredients of the paniculate, including masking the taste of therapeutically active compounds, granulating materials or any excipients.
- a coating may also be used to provide for the controlled release of the therapeutically active compounds from the fine particulate.
- the fine particle produced by the disclosed method have the advantages that they have an improved mouth feel; i.e., the particle do not feel gritty or abrasive to the patient.
- the surface of the particles are also more uniform than particles produced by prior art methods and therefore are more readily coated, if desired.
- the fine particles produced by the present method have improved chemical stability of the therapeutically active compound.
- fine particulate may be useful in agriculture to deliver a therapeutically active compound, a fertilizer, or other agents to plants. It is intended that other such applications which employ the fine particles of the present invention fall within the scope of this invention.
- the dry ingredients are thoroughly blended. On a small scale the dry blending may be carried out in stainless steel bowls. For larger quantities, dry mixing of the ingredients may be conveniently carried out in a twin- shell belnder of the Patterson-Kelley type. Planetary mixers, for example a Glen mixer or a Hobart mixer, are also conveniently used. The resulting dry mixture is then wetted by addition of sufficient wetting fluid
- the wetting step is carried out in batches in mixers of the type described above or, conventional equipment which permits the continuous uniform moisturization of the dry blend.
- the granulated powder is then fed by auger to conventional extruding equipment where the solid is extruded at high shear through screens of the appropriate mesh size to form threads of the drug formulation.
- Typical of extrusion equipment for this step is the Model EXDCS-10 Extruder manufactured by Fuji Paudal Co., Ltd.
- the product at this stage of the process is in the form of long strands of spaghetti-like drug formulation, with the strands having the diameter of the extrusion mesh.
- the strands of drug formulation from the previous step are collected and fed to a spheronizing apparatus, typified by the Marumerizer, manufacterued by the Fuji Paudal Co. Ltd. or the CF Granulator manufactured by the Vector Corporation.
- a spheronizing apparatus typified by the Marumerizer, manufacterued by the Fuji Paudal Co. Ltd. or the CF Granulator manufactured by the Vector Corporation.
- Microcrystalline cellulose or other excipients may be added to the formulation mixture at this point to dust the material to prevent agglomeration.
- the spheronizer tumbles the spaghetti-like strands of drug formulation, breaking them up into spheroids of the general diameter of the strands or smaller.
- the spheroids of drug formulation produced in the prior step are then dried in a conventional fluid bed dryer such as that manufactured by Niro, Inc.
- a conventional fluid bed dryer such as that manufactured by Niro, Inc.
- the particles are passed through seives for sizing.
- the fine particles may then be incorporated into conventional pharmaceutical formulations as cachets, capsules, or by formulation into tablets or caplets.
- the extrusion screens flexed but did not rupture. Moreover, greater than 70% of the fine particles which were produced were in the desired range of 40-60 mesh.
- the drug zileuton is characteristically more easily extruded, but in formulation
- compositions were prepared using zileuton (i.e. N-hydroxy-N-2-((benzo[b]thien-2-yl)ethyl)urea), excipients, disintegrating agents, binders, water, and the preferred extrusion aid material (glyceryl behenate) in accordance with the present invention.
- the compositions contained water in amounts ranging between 520 ml per kg of formulation (34.2% by weight) to 760 ml per kg of formulation (43.2% by weight).
- the formulation compositions are presented in Table 2.
- Zileuton is N-hydroxy-N-2-((benzo[b]thien-2-yl)ethyl)urea /22319
- the compositions were extruded successfully through a 0.5 mm mesh screen to produce fine particle formulations having substantially uniform particle size.
- the generally accepted teachings in the art are that the amount of wetting fluid (e.g. water) contained in the formulation at the time of extrusion is a critical factor in determining success of extrusion and microparticle spheroid size and shape (cf. L. C. Wan, et al.. report in the International Journal of Pharmaceutics. 96: 59-65 (1993)).
- the data shown in Table 2 indicate that when an extrusion aid is incorporated into formulations made in accordance with the process of the present invention, the amount of wetting fluid (e.g.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX9603480A MX9603480A (en) | 1994-02-16 | 1995-02-14 | Process for preparing fine particle pharmaceutical formulations. |
JP52190295A JP4040084B2 (en) | 1994-02-16 | 1995-02-14 | Process for the preparation of particulate pharmaceutical formulations |
DK95909559T DK0744941T3 (en) | 1994-02-16 | 1995-02-14 | Process for preparing finely divided pharmaceutical formulations |
CA002182282A CA2182282C (en) | 1994-02-16 | 1995-02-14 | Process for preparing fine particle pharmaceutical formulations |
AT95909559T ATE241962T1 (en) | 1994-02-16 | 1995-02-14 | METHOD FOR PRODUCING FINE PARTICLE PHARMACEUTICAL FORMULATIONS |
EP95909559A EP0744941B1 (en) | 1994-02-16 | 1995-02-14 | Process for preparing fine particle pharmaceutical formulations |
DE69530973T DE69530973T2 (en) | 1994-02-16 | 1995-02-14 | METHOD FOR PRODUCING FINE-PART PHARMACEUTICAL FORMULATIONS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19702594A | 1994-02-16 | 1994-02-16 | |
US08/197,025 | 1994-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995022319A1 true WO1995022319A1 (en) | 1995-08-24 |
Family
ID=22727703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/001943 WO1995022319A1 (en) | 1994-02-16 | 1995-02-14 | Process for preparing fine particle pharmaceutical formulations |
Country Status (11)
Country | Link |
---|---|
US (1) | US6063313A (en) |
EP (1) | EP0744941B1 (en) |
JP (1) | JP4040084B2 (en) |
AT (1) | ATE241962T1 (en) |
CA (1) | CA2182282C (en) |
DE (1) | DE69530973T2 (en) |
DK (1) | DK0744941T3 (en) |
ES (1) | ES2199981T3 (en) |
MX (1) | MX9603480A (en) |
PT (1) | PT744941E (en) |
WO (1) | WO1995022319A1 (en) |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997007786A2 (en) * | 1995-08-25 | 1997-03-06 | Basf Aktiengesellschaft | Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process |
FR2753904A1 (en) * | 1996-10-01 | 1998-04-03 | Gattefosse Ets Sa | PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE OF ACTIVE PRINCIPLE, INCLUDING A MATRIX, AND MANUFACTURING PROCESS |
WO2000048607A1 (en) * | 1999-02-19 | 2000-08-24 | LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. | Directly compressible matrix for controlled release of single daily doses of clarithromycin |
WO2000057853A2 (en) * | 1999-03-31 | 2000-10-05 | Schering Ag | Pharmaceutical composition containing an extrusion additive |
US6139872A (en) * | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
WO2002024174A2 (en) * | 2000-09-22 | 2002-03-28 | Galephar M/F | Sustained release composition containing clarithromycin |
US6365216B1 (en) | 1999-03-26 | 2002-04-02 | The Nutrasweet Company | Particles of N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester |
US6488963B1 (en) | 1996-06-26 | 2002-12-03 | The University Of Texas System | Hot-melt extrudable pharmaceutical formulation |
WO2005023221A1 (en) * | 2003-09-05 | 2005-03-17 | Ranbaxy Laboratories Limited | Clarithromycin formulations having improved biovailability |
EP1729812A1 (en) | 2004-02-27 | 2006-12-13 | Niche Generics Limited | Stable pharmaceutical composition comprising an ace inhibitor |
US7476403B2 (en) | 2003-06-16 | 2009-01-13 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US7820722B2 (en) | 2001-05-11 | 2010-10-26 | Merrion Research Iii Limited | Permeation enhancers |
US7829122B2 (en) | 2000-11-16 | 2010-11-09 | Ethypharm | Microgranules based on active principle and method for making same |
US8114383B2 (en) | 2003-08-06 | 2012-02-14 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US8268349B2 (en) | 2003-08-28 | 2012-09-18 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8323889B2 (en) | 2004-07-01 | 2012-12-04 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
US8470347B2 (en) | 2000-05-30 | 2013-06-25 | AbbVie Deutschland GmbH and Co KG | Self-emulsifying active substance formulation and use of this formulation |
US8802114B2 (en) | 2011-01-07 | 2014-08-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
US8834925B2 (en) | 2006-08-25 | 2014-09-16 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8883201B2 (en) | 2006-04-07 | 2014-11-11 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US8999383B2 (en) | 2008-05-07 | 2015-04-07 | Merrion Research Iii Limited | Compositions of GnRH related compounds and processes of preparation |
US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
US9107830B2 (en) | 1999-11-12 | 2015-08-18 | Abbvie, Inc. | Inhibitors of crystallization in a solid dispersion |
US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1298574B1 (en) * | 1998-02-06 | 2000-01-12 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF POLYMER-BASED MICROPARTICLES OBTAINED BY EXTRUSION AND SPHERONIZATION |
DK1073513T3 (en) * | 1998-04-24 | 2003-12-22 | Basf Corp | Improved extrusion process |
JP2000128774A (en) * | 1998-10-26 | 2000-05-09 | Tanabe Seiyaku Co Ltd | Production of globular, fine grain including medicine |
WO2001072284A1 (en) * | 2000-03-28 | 2001-10-04 | Biochemie Gesellschaft M.B.H. | Granulated particles with masked taste |
ITRN20000051A1 (en) | 2000-12-22 | 2002-06-22 | Ascor Chimici Srl | METHOD AND EQUIPMENT TO FORM COMPOSITE SPHERES CONTAINING ACTIVE INGREDIENTS OF THE PHARMACEUTICAL TYPE AND / OR FOOD OR COSMETIC SUPPLEMENTS |
US20030203019A1 (en) * | 2002-04-30 | 2003-10-30 | Cornelius John Mark | Coated conditioners for use in foods and pharmaceuticals |
EP1594470A4 (en) * | 2003-02-19 | 2007-10-17 | Biovail Lab Int Srl | Rapid absorption selective 5-ht agonist formulations |
US20060165790A1 (en) * | 2003-06-27 | 2006-07-27 | Malcolm Walden | Multiparticulates |
TWI357815B (en) * | 2003-06-27 | 2012-02-11 | Euro Celtique Sa | Multiparticulates |
US7491263B2 (en) * | 2004-04-05 | 2009-02-17 | Technology Innovation, Llc | Storage assembly |
GB2418854B (en) | 2004-08-31 | 2009-12-23 | Euro Celtique Sa | Multiparticulates |
DE102006006532B4 (en) * | 2006-02-10 | 2007-11-08 | Biogenerics Pharma Gmbh | Pharmaceutical preparation |
US20080131504A1 (en) * | 2006-12-01 | 2008-06-05 | Mission Pharmacal Co. | Short Term Slow Release Drug Delivery System |
US9163133B2 (en) * | 2009-12-23 | 2015-10-20 | Essilor International (Compagnie Générale d'Optique) | Method of converting a polymerizable composition into thermoplastic polyurethane of improved yellowness index and article obtained by this method |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB757165A (en) * | 1953-10-30 | 1956-09-12 | Abbott Lab | Compositions of erythromycin for combating bacterial infections |
EP0204596A1 (en) * | 1985-05-09 | 1986-12-10 | Rhone-Poulenc Sante | Compositions for the preparation of microparticles by extrusion for the sustained release of biologically active substances, and microparticles so obtained |
US4755385A (en) * | 1985-07-10 | 1988-07-05 | Dr. Karl Thomae, Gmbh | Oral pharmaceutical preparations containing 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin |
EP0350701A2 (en) * | 1988-07-12 | 1990-01-17 | FARMA RESA S.r.l. | Pharmaceutical cmpositions for oral administration having analgesic and anti-inflammatory activity, possessing excellent palatability and being free of irritating effects on mucous membranes |
EP0438359A1 (en) * | 1990-01-19 | 1991-07-24 | Aventis Pharma S.A. | Process for preparing pearl-shaped drugs |
EP0465338A1 (en) * | 1990-06-29 | 1992-01-08 | Rhone-Poulenc Nutrition Animale | Process for the preparation of granulates of actives through extrusion |
WO1993017667A1 (en) * | 1992-03-12 | 1993-09-16 | Taisho Pharmaceutical Co., Ltd. | Composition for oral preparations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4374082A (en) * | 1981-08-18 | 1983-02-15 | Richard Hochschild | Method for making a pharmaceutical and/or nutritional dosage form |
US4686231A (en) * | 1985-12-12 | 1987-08-11 | Smithkline Beckman Corporation | Inhibition of 5-lipoxygenase products |
US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
IL84944A (en) * | 1987-01-19 | 1992-02-16 | Ici Plc | Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation |
US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
US5002774A (en) * | 1989-06-08 | 1991-03-26 | Erbamont, Inc. | Sustained release pharmaceutical tablet |
US5169645A (en) * | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
US5292900A (en) * | 1992-12-18 | 1994-03-08 | Abbott Laboratories | O-substituted N-hydroxyurea derivatives |
-
1995
- 1995-02-14 MX MX9603480A patent/MX9603480A/en not_active IP Right Cessation
- 1995-02-14 JP JP52190295A patent/JP4040084B2/en not_active Expired - Fee Related
- 1995-02-14 DK DK95909559T patent/DK0744941T3/en active
- 1995-02-14 DE DE69530973T patent/DE69530973T2/en not_active Expired - Fee Related
- 1995-02-14 AT AT95909559T patent/ATE241962T1/en not_active IP Right Cessation
- 1995-02-14 ES ES95909559T patent/ES2199981T3/en not_active Expired - Lifetime
- 1995-02-14 CA CA002182282A patent/CA2182282C/en not_active Expired - Fee Related
- 1995-02-14 PT PT95909559T patent/PT744941E/en unknown
- 1995-02-14 WO PCT/US1995/001943 patent/WO1995022319A1/en active IP Right Grant
- 1995-02-14 EP EP95909559A patent/EP0744941B1/en not_active Expired - Lifetime
-
1996
- 1996-05-30 US US08/655,491 patent/US6063313A/en not_active Expired - Lifetime
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB757165A (en) * | 1953-10-30 | 1956-09-12 | Abbott Lab | Compositions of erythromycin for combating bacterial infections |
EP0204596A1 (en) * | 1985-05-09 | 1986-12-10 | Rhone-Poulenc Sante | Compositions for the preparation of microparticles by extrusion for the sustained release of biologically active substances, and microparticles so obtained |
US4755385A (en) * | 1985-07-10 | 1988-07-05 | Dr. Karl Thomae, Gmbh | Oral pharmaceutical preparations containing 9-deoxo-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)-ethylidene]-oxy]-(9S)-erythromycin |
EP0350701A2 (en) * | 1988-07-12 | 1990-01-17 | FARMA RESA S.r.l. | Pharmaceutical cmpositions for oral administration having analgesic and anti-inflammatory activity, possessing excellent palatability and being free of irritating effects on mucous membranes |
EP0438359A1 (en) * | 1990-01-19 | 1991-07-24 | Aventis Pharma S.A. | Process for preparing pearl-shaped drugs |
EP0465338A1 (en) * | 1990-06-29 | 1992-01-08 | Rhone-Poulenc Nutrition Animale | Process for the preparation of granulates of actives through extrusion |
WO1993017667A1 (en) * | 1992-03-12 | 1993-09-16 | Taisho Pharmaceutical Co., Ltd. | Composition for oral preparations |
Cited By (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997007786A3 (en) * | 1995-08-25 | 1997-04-03 | Basf Ag | Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process |
WO1997007786A2 (en) * | 1995-08-25 | 1997-03-06 | Basf Aktiengesellschaft | Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process |
US6387401B2 (en) | 1995-08-25 | 2002-05-14 | Basf Aktiengesellschaft | Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process |
US6488963B1 (en) | 1996-06-26 | 2002-12-03 | The University Of Texas System | Hot-melt extrudable pharmaceutical formulation |
US6139872A (en) * | 1996-08-14 | 2000-10-31 | Henkel Corporation | Method of producing a vitamin product |
FR2753904A1 (en) * | 1996-10-01 | 1998-04-03 | Gattefosse Ets Sa | PHARMACEUTICAL COMPOSITION WITH MODIFIED RELEASE OF ACTIVE PRINCIPLE, INCLUDING A MATRIX, AND MANUFACTURING PROCESS |
WO2000048607A1 (en) * | 1999-02-19 | 2000-08-24 | LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. | Directly compressible matrix for controlled release of single daily doses of clarithromycin |
CZ302781B6 (en) * | 1999-02-19 | 2011-11-02 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov D. D. | Pharmaceutical formulation for controlled release of single daily dose of active substance, process for preparing such pharmaceutical formulation and the use thereof in the treatment and prophylaxis |
HRP20010684B1 (en) * | 1999-02-19 | 2011-01-31 | Lek | Directly compressible matrix for controlled release of single daily doses of clarithromycin |
AU776912B2 (en) * | 1999-02-19 | 2004-09-23 | Lek Farmacevtska Druzba D.D. | Directly compressible matrix for controlled release of single daily doses of clarithromycin |
US8828431B2 (en) | 1999-02-22 | 2014-09-09 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US8323690B2 (en) | 1999-02-22 | 2012-12-04 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US8053429B2 (en) | 1999-02-22 | 2011-11-08 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US8323689B2 (en) | 1999-02-22 | 2012-12-04 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US7658938B2 (en) * | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US6365216B1 (en) | 1999-03-26 | 2002-04-02 | The Nutrasweet Company | Particles of N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine 1-methyl ester |
WO2000057853A2 (en) * | 1999-03-31 | 2000-10-05 | Schering Ag | Pharmaceutical composition containing an extrusion additive |
WO2000057853A3 (en) * | 1999-03-31 | 2001-02-22 | Schering Ag | Pharmaceutical composition containing an extrusion additive |
JP2002540138A (en) * | 1999-03-31 | 2002-11-26 | シエーリング アクチエンゲゼルシャフト | Pharmaceutical compositions containing extrusion additives |
US9107830B2 (en) | 1999-11-12 | 2015-08-18 | Abbvie, Inc. | Inhibitors of crystallization in a solid dispersion |
US8470347B2 (en) | 2000-05-30 | 2013-06-25 | AbbVie Deutschland GmbH and Co KG | Self-emulsifying active substance formulation and use of this formulation |
WO2002024174A2 (en) * | 2000-09-22 | 2002-03-28 | Galephar M/F | Sustained release composition containing clarithromycin |
WO2002024174A3 (en) * | 2000-09-22 | 2002-09-26 | Galephar M F | Sustained release composition containing clarithromycin |
US7829122B2 (en) | 2000-11-16 | 2010-11-09 | Ethypharm | Microgranules based on active principle and method for making same |
US7820722B2 (en) | 2001-05-11 | 2010-10-26 | Merrion Research Iii Limited | Permeation enhancers |
US8039444B2 (en) | 2001-05-11 | 2011-10-18 | Isis Pharmaceuticals, Inc. | Antisense permeation enhancers |
US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
US8628797B2 (en) | 2003-06-16 | 2014-01-14 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
US7476403B2 (en) | 2003-06-16 | 2009-01-13 | Andrx Pharmaceuticals, Llc | Oral extended-release composition |
US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
US8114383B2 (en) | 2003-08-06 | 2012-02-14 | Gruenenthal Gmbh | Abuse-proofed dosage form |
US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
US8399015B2 (en) | 2003-08-28 | 2013-03-19 | Abbvie Inc. | Solid pharmaceutical dosage form |
US8333990B2 (en) | 2003-08-28 | 2012-12-18 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8268349B2 (en) | 2003-08-28 | 2012-09-18 | Abbott Laboratories | Solid pharmaceutical dosage form |
US8691878B2 (en) | 2003-08-28 | 2014-04-08 | Abbvie Inc. | Solid pharmaceutical dosage form |
US8309613B2 (en) | 2003-08-28 | 2012-11-13 | Abbvie Inc. | Solid pharmaceutical dosage form |
WO2005023221A1 (en) * | 2003-09-05 | 2005-03-17 | Ranbaxy Laboratories Limited | Clarithromycin formulations having improved biovailability |
US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
EP1729812A1 (en) | 2004-02-27 | 2006-12-13 | Niche Generics Limited | Stable pharmaceutical composition comprising an ace inhibitor |
US8323889B2 (en) | 2004-07-01 | 2012-12-04 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
US8883203B2 (en) | 2006-04-07 | 2014-11-11 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US8883201B2 (en) | 2006-04-07 | 2014-11-11 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
US9486413B2 (en) | 2006-08-25 | 2016-11-08 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US10076498B2 (en) | 2006-08-25 | 2018-09-18 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9095614B2 (en) | 2006-08-25 | 2015-08-04 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8846086B2 (en) | 2006-08-25 | 2014-09-30 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9486412B2 (en) | 2006-08-25 | 2016-11-08 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9095615B2 (en) | 2006-08-25 | 2015-08-04 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9492391B2 (en) | 2006-08-25 | 2016-11-15 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9492389B2 (en) | 2006-08-25 | 2016-11-15 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9492393B2 (en) | 2006-08-25 | 2016-11-15 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9492390B2 (en) | 2006-08-25 | 2016-11-15 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9492392B2 (en) | 2006-08-25 | 2016-11-15 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9545380B2 (en) | 2006-08-25 | 2017-01-17 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8894988B2 (en) | 2006-08-25 | 2014-11-25 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8834925B2 (en) | 2006-08-25 | 2014-09-16 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9101661B2 (en) | 2006-08-25 | 2015-08-11 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9084816B2 (en) | 2006-08-25 | 2015-07-21 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11938225B2 (en) | 2006-08-25 | 2024-03-26 | Purdue Pharm L.P. | Tamper resistant dosage forms |
US11298322B2 (en) | 2006-08-25 | 2022-04-12 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9763933B2 (en) | 2006-08-25 | 2017-09-19 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9763886B2 (en) | 2006-08-25 | 2017-09-19 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9770417B2 (en) | 2006-08-25 | 2017-09-26 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9770416B2 (en) | 2006-08-25 | 2017-09-26 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9775811B2 (en) | 2006-08-25 | 2017-10-03 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9775808B2 (en) | 2006-08-25 | 2017-10-03 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9775812B2 (en) | 2006-08-25 | 2017-10-03 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9775809B2 (en) | 2006-08-25 | 2017-10-03 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9775810B2 (en) | 2006-08-25 | 2017-10-03 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8911719B2 (en) | 2006-08-25 | 2014-12-16 | Purdue Pharma Lp | Tamper resistant dosage forms |
US11826472B2 (en) | 2006-08-25 | 2023-11-28 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11304909B2 (en) | 2006-08-25 | 2022-04-19 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US8894987B2 (en) | 2006-08-25 | 2014-11-25 | William H. McKenna | Tamper resistant dosage forms |
US10076499B2 (en) | 2006-08-25 | 2018-09-18 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US11304908B2 (en) | 2006-08-25 | 2022-04-19 | Purdue Pharma L.P. | Tamper resistant dosage forms |
US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
US8999383B2 (en) | 2008-05-07 | 2015-04-07 | Merrion Research Iii Limited | Compositions of GnRH related compounds and processes of preparation |
US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
US9089484B2 (en) | 2010-03-26 | 2015-07-28 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor Xa inhibitors for oral administration |
US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
US8802114B2 (en) | 2011-01-07 | 2014-08-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
US10265384B2 (en) | 2015-01-29 | 2019-04-23 | Novo Nordisk A/S | Tablets comprising GLP-1 agonist and enteric coating |
US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
Also Published As
Publication number | Publication date |
---|---|
JPH09509176A (en) | 1997-09-16 |
DE69530973D1 (en) | 2003-07-10 |
ES2199981T3 (en) | 2004-03-01 |
DK0744941T3 (en) | 2003-09-29 |
CA2182282C (en) | 2006-04-18 |
EP0744941B1 (en) | 2003-06-04 |
CA2182282A1 (en) | 1995-08-24 |
EP0744941A1 (en) | 1996-12-04 |
PT744941E (en) | 2003-10-31 |
JP4040084B2 (en) | 2008-01-30 |
US6063313A (en) | 2000-05-16 |
ATE241962T1 (en) | 2003-06-15 |
MX9603480A (en) | 1997-12-31 |
DE69530973T2 (en) | 2004-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6063313A (en) | Process for the preparation of fine particle pharmaceutical formulations | |
JP3267561B2 (en) | Use of tramadol or a pharmaceutically acceptable salt thereof and analgesic | |
AU722358B2 (en) | Sustained release compositions and a method of preparing pharmaceutical compositions | |
CA2065210C (en) | Controlled release matrix for pharmaceuticals | |
KR100232945B1 (en) | Melt-extruded orally administrable opioid formulations | |
CA2477890C (en) | Immediate release pharmaceutical granule compositions and a continuous process for making them | |
US8506998B2 (en) | Pharmaceutical formulation | |
US6143328A (en) | Sustained release compositions and a method of preparing pharmaceutical compositions | |
JPH0122245B2 (en) | ||
EP0797435A1 (en) | Controlled release matrix for pharmaceuticals | |
NZ260883A (en) | Oral sustained-release medicaments containing morphine | |
KR20000069356A (en) | Immediate Release Drug Delivery forms | |
GB2190287A (en) | Oral ketoprofen formulation | |
JP2006514672A (en) | Controlled release formulation containing hydrophobic substance as sustained release agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2182282 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995909559 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995909559 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995909559 Country of ref document: EP |